| Identification | Back Directory | [Name]
Pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione, 2-cyclobutyl-10-methyl-3-phenyl- | [CAS]
1613509-49-1 | [Synonyms]
Pyrimido[4,5-b]quinoline-4,5(3H,10H)-dione, 2-cyclobutyl-10-methyl-3-phenyl- | [Molecular Formula]
C22H19N3O2 | [MOL File]
1613509-49-1.mol | [Molecular Weight]
357.41 |
| Chemical Properties | Back Directory | [Boiling point ]
495.3±55.0 °C(Predicted) | [density ]
1.35±0.1 g/cm3(Predicted) | [form ]
Solid | [pka]
2.41±0.20(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
SRI-41315 is a small molecule that induces translational readthrough of CFTR nonsense mutations by eRF1 depletion. SRI-41315 induce a prolonged pause at stop codons and suppress PTCs associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells, restoring CFTR expression and function. SRI-41315 suppresses PTCs by reducing the abundance of the termination factor eRF1. SRI-41315 also potentiates aminoglycoside-mediated readthrough, leading to synergistic increases in CFTR activity. |
|
|